Tags » Hematopoietic Stem Cell Transplantation

Fate Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, May 20, 2015 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $5.00 per share, before underwriting discounts, for an aggregate offering of $30 million. 493 more words

Other Funding

Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow

HAIFA, Israel, May 6, 2015 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. 362 more words

Intellectual Property

BioLineRx Reports Successful Top-Line Safety and Efficacy Results for Novel Stem Cell Mobilization Treatment

JERUSALEM–(BUSINESS WIRE)–BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today successful top-line results from the Phase 1 safety and efficacy study of its lead clinical candidate, BL-8040, as a novel approach for mobilization and collection of bone-marrow stem cells from the peripheral blood circulation. 1,105 more words

Preclinical & Clinical

BioLineRx Reports Year End 2014 Financial Results

JERUSALEM–(BUSINESS WIRE)–BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2014. 1,467 more words

Preclinical & Clinical

BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares

JERUSALEM–(BUSINESS WIRE)–BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its previously announced underwritten public offering of 14,375,000 American Depositary Shares (“ADSs”), each representing ten (10) of its Ordinary Shares, at a public offering price of $2.00 per ADS, for gross proceeds of $28.75 million. 418 more words

Acute Myeloid Leukemia

Fate Therapeutics Expands and Strengthens Leadership Team

SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Wendy Levin, M.D., M.S. 556 more words

Management & Board Appointments